Latest News on VIR

Financial News Based On Company


Advertisement
Advertisement

VIR: ECLIPSE 1 data fuel a planned 2027 HDV filing and oncology pivotal trials

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4681405:0-vir-eclipse-1-data-fuel-a-planned-2027-hdv-filing-and-oncology-pivotal-trials/
Vir Biotechnology (VIR) announced that ECLIPSE 1 data, showing nearly 80% undetectable viral RNA at week 48, supports a planned HDV filing in mid-2027, with results expected in Q1 2027. The company is also targeting oncology pivotal trials for 2027, bolstered by PRO-XTEN collaborations and a cash runway extending into 2029. This information is based on their Jefferies Global Healthcare Conference Audio Transcript from November 18, 2026.

CFO Aziz Sawaf receives 75,000 restricted stock units plus stock options at Vir Biotechnology (VIR).

https://www.stocktitan.net/sec-filings/VIR/form-4-vir-biotechnology-inc-insider-trading-activity-8a9b16f1a98e.html
Vir Biotechnology's EVP and Chief Financial Officer, Aziz Sawaf, was granted 75,000 restricted stock units (RSUs) and stock options covering 150,000 common shares on November 15, 2026. The stock options have an exercise price of $9.96 and expire on November 14, 2036. Vesting for 25% of both awards begins on November 15, 2027, with the remaining RSUs vesting in three equal annual installments and options vesting in 36 equal monthly installments.

Accounting chief at Vir Biotechnology (VIR) gets 50,000 stock units; vesting starts in November 2027.

https://www.stocktitan.net/sec-filings/VIR/form-4-vir-biotechnology-inc-insider-trading-activity-276cedff1b74.html
Brent Sabatini, SVP and Chief Accounting Officer at Vir Biotechnology (VIR), acquired 50,000 restricted stock units (RSUs) on November 15, 2026, as part of the company's Equity Incentive Plan. His direct holdings now total 111,902 shares. The RSUs will vest in installments, with 25% vesting on November 15, 2027, and the remainder vesting in three equal annual installments thereafter.

Vir Biotechnology (VIR) adds Exhibit 107; other prospectus information is unchanged.

https://www.stocktitan.net/sec-filings/VIR/424b5-vir-biotechnology-inc-prospectus-supplement-debt-securities-3dca176ac563.html
Vir Biotechnology, Inc. (VIR) filed a supplement to its November 12, 2026 prospectus to add an inadvertently omitted Exhibit 107. The company explicitly stated that this supplement does not modify or update any other information contained in the original filing. This SEC filing was made pursuant to Rule 424(b)(5) under the Securities Act.

Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock

https://legaldesire.com/latham-watkins-advises-on-vir-biotechnologys-us150-million-public-offering-of-common-stock/
Latham & Watkins LLP advised the underwriters in Vir Biotechnology, Inc.'s US$150 million underwritten public offering of 15,000,000 shares of its common stock at US$10 per share. Vir Biotechnology, a clinical-stage biopharmaceutical company, also granted underwriters a 30-day option for an additional 2,250,000 shares. The offering's closing was expected on November 16, 2026, subject to customary conditions.
Advertisement

Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale

https://www.tradingview.com/news/gurufocus:8d97d220d094b:0-vir-biotechnology-shares-drop-as-biotech-firm-moves-ahead-with-stock-sale/
Vir Biotechnology shares fell 10% after the company announced terms for a public stock sale, aiming to raise $150 million initially, with a potential increase to $172.5 million if underwriters exercise their option. This offering involves selling 15 million common shares at $10 each, plus an additional 2.25 million shares option. While the sale provides capital, it also expands the share count, potentially diluting existing shareholders' ownership.

Vir Biotechnology Announces Proposed Public Offering - November 12, 2026

https://www.biospace.com/press-releases/vir-biotechnology-announces-proposed-public-offering-november-12-2026
Vir Biotechnology, Inc. announced its intention to offer shares of its common stock in an underwritten public offering, with an option for underwriters to purchase an additional 15%. The offering is subject to market and other conditions, and all shares will be offered by Vir Biotechnology. Leerink Partners, Morgan Stanley, and Evercore ISI are acting as bookrunning managers.

Vir Biotechnology stock tumbles on $150M share offering

https://www.investing.com/news/stock-market-news/vir-biotechnology-stock-tumbles-on-150m-share-offering-5025817
Vir Biotechnology Inc (NASDAQ:VIR) shares fell 15% in premarket trading after the company announced a $150 million public stock offering, selling 15 million shares at $10 each. The clinical-stage biopharmaceutical company also granted underwriters an option to purchase an additional 2.25 million shares. The offering is expected to close on November 16, 2026, with Leerink Partners, Morgan Stanley, and Evercore ISI acting as bookrunners.

Vir Biotechnology Shares Slide After $150 Million Stock Sale Priced at $10

https://finance.biggo.com/news/af5494e4-fd05-4078-86c0-42396e21db2d
Vir Biotechnology's shares dropped 15% in premarket trading after the company priced a $150 million public stock offering of 15 million shares at $10 each, leading to investor concern over dilution. The offering is expected to close on November 16, 2026, with proceeds funding its pipeline of hepatitis delta and oncology treatments. Despite the stock sale, analysts maintain a Buy consensus with an average price target of $24, citing upcoming clinical and regulatory milestones as key catalysts.

Vir Biotechnology stock tumbles on $150M share offering

https://finance.yahoo.com/markets/stocks/articles/vir-biotechnology-stock-tumbles-150m-145743749.html
Vir Biotechnology Inc. (NASDAQ:VIR) shares dropped 15% in premarket trading after the company announced a $150 million public stock offering priced at $10 per share. The biopharmaceutical company will sell 15 million shares, with underwriters having an option to purchase an additional 2.25 million shares. The offering is expected to close on November 16, 2026, and the proceeds will support Vir Biotechnology's focus on developing medicines for infectious diseases and cancer.
Advertisement

Why Is Vir Biotechnology Stock Falling Friday?

https://www.benzinga.com/markets/offerings/26/11/63236510/why-is-vir-biotechnology-stock-falling-friday
Vir Biotechnology's stock fell in Friday's premarket trading after the company announced a $150 million public stock offering at $10 per share, raising concerns about shareholder dilution. Despite this short-term bearish pressure, the company has reported positive Phase 3 results for its hepatitis delta combination treatment and received FDA Fast Track designation for a prostate cancer candidate, with analysts maintaining a consensus Buy rating. The stock has seen significant gains over the past year, reflecting a mixed technical outlook.

Vir Biotechnology prices $150M public stock offering at $10 per share

https://www.streetinsider.com/Equity+Offerings/Vir+Biotechnology+prices+%24150M+public+stock+offering+at+%2410+per+share/27338145.html
Vir Biotechnology, Inc. has priced an underwritten public offering of 15,000,000 shares of common stock at $10.00 per share, aiming to raise $150 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase an additional 2,250,000 shares. The offering is expected to close on November 16, 2026, with Leerink Partners, Morgan Stanley, and Evercore ISI acting as bookrunning managers.

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

https://quantisnow.com/insight/vir-biotechnology-announces-pricing-of-public-offering-of-common-stock-6789068
Vir Biotechnology has priced an underwritten public offering of 15,000,000 common shares at $10.00 each, expecting to raise $150 million in gross proceeds. The offering is anticipated to close on November 16, 2026, and includes an over-allotment option for underwriters to purchase an additional 2,250,000 shares. This offering will dilute existing shareholders' ownership as all shares are newly issued by the company.

Vir Biotechnology Drops 7.5% After Morgan Stanley Maintains Overweight

https://news.alphastreet.com/vir-biotechnology-drops-7-5-after-morgan-stanley-maintains-overweight/
Vir Biotechnology shares fell 7.5% despite several Wall Street firms raising their price targets, indicating a puzzling disconnect between analyst sentiment and market action. Morgan Stanley maintained its Overweight rating and increased its target from $25 to $28, with other firms also boosting targets. The average new price target of $25 suggests substantial upside, but factors like broader portfolio repositioning or profit-taking might explain the stock's decline.

Vir Biotechnology (VIR) may sell securities directly or through agents, underwriters or dealers.

https://www.stocktitan.net/sec-filings/VIR/s-3asr-vir-biotechnology-inc-sec-filing-628cd0d97159.html
Vir Biotechnology Inc. has registered a shelf prospectus to offer various securities including debt, common stock, preferred stock, and warrants. These securities may be sold periodically through agents, underwriters, or directly, with specific terms to be detailed in prospectus supplements. The company plans to use the net proceeds for general corporate purposes, including working capital, research and development, and clinical expenses.
Advertisement

Vir Biotechnology Inc. (VIR) files mixed shelf

https://www.streetinsider.com/Corporate+News/Vir+Biotechnology+Inc.+%28VIR%29+files+mixed+shelf/27336391.html
Vir Biotechnology Inc. (NASDAQ: VIR) has filed a mixed shelf offering, which includes Debt Securities, Common Stock, Preferred Stock, and Warrants. This financial move allows the company flexibility to raise capital in the future. The stock's price was $12.12, down 7.69%, with an overall analyst rating of SELL.

A 7.82 million-share stake in Vir Biotechnology (VIR) is reported by State Street.

https://www.stocktitan.net/sec-filings/VIR/schedule-13g-vir-biotechnology-inc-passive-investment-disclosure-5-69a418144fc3.html
State Street Corporation has reported a beneficial ownership of 7,822,781 shares, representing 4.6% of Vir Biotechnology, Inc. (VIR) as of September 30, 2026. This Schedule 13G filing indicates shared voting power over 7,507,527 shares and shared dispositive power over all 7,822,781 shares. The report also lists the subsidiaries through which this ownership is managed.

VIR: Vir Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

https://www.quantisnow.com/insight/vir-biotechnology-inc-filed-sec-form-8-k-regulation-fd-disclosure-6780531
Vir Biotechnology announced that its pivotal Phase 3 ECLIPSE 1 trial for elebsiran and tobevibart in chronic hepatitis delta met its primary endpoint, with 44% of patients achieving a response at Week 48. Additionally, expanded Phase 2 SOLSTICE data showed 100% of patients who completed Week 96 reached undetectable viremia. The company is holding an investor call to discuss these positive topline results.

Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success

https://www.investing.com/news/stock-market-news/vir-biotechnology-stock-jumps-22-after-hepatitis-delta-phase-3-trial-success-5011761
Vir Biotechnology (NASDAQ: VIR) shares surged 22% after its Phase 3 ECLIPSE 1 trial for elebsiran and tobevibart in chronic hepatitis delta met all primary and key secondary endpoints. The drug combination led to undetectable virus levels and normalized ALT in 44% of patients at Week 48, with 79% achieving undetectable virus levels overall. The combination was well-tolerated, and additional positive data from the Phase 2 SOLSTICE trial was also released.

Why Is Vir Biotechnology Stock Trading Higher Today? - Vir Biotechnology (NASDAQ:VIR)

https://www.benzinga.com/trading-ideas/movers/26/11/63039953/vir-biotech-highlights-significant-viral-suppression-in-advanced-liver-disease-study
Vir Biotechnology Inc. (NASDAQ: VIR) announced positive topline results from its pivotal Phase 3 ECLIPSE 1 study for chronic hepatitis delta, showing significant viral suppression and a favorable safety profile. The dual regimen of elebsiran and tobevibart achieved a 44% response rate for undetectable virus and alanine aminotransferase normalization at Week 48. These positive findings have led to a substantial increase in Vir Biotechnology's stock price, with plans for a global regulatory filing by mid-2027.
Advertisement

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

https://www.biospace.com/press-releases/vir-biotechnology-announces-primary-endpoint-met-in-pivotal-phase-3-eclipse-1-trial-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta
Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial, demonstrating that the elebsiran and tobevibart combination regimen met its primary endpoint in treating chronic hepatitis delta (CHD). At Week 48, 44% of patients achieved undetectable virus and ALT normalization, with 79% reaching undetectable virus, showing significant improvement compared to the delayed treatment group. The regimen was well-tolerated, and a comprehensive regulatory filing package is planned for U.S. FDA submission in mid-2027.

VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets

https://stocktwits.com/news-articles/markets/equity/vir-stock-best-year-ever-hepatitis-win-buyout-bigger-bullish-bets/cNGA6fER9eI
Shares of Vir Biotechnology (VIR) surged over 10% after positive Phase 3 trial results for its hepatitis delta combination treatment, Elebsiran and Tobevibart. The trial met all endpoints, showing robust viral suppression and potential for a finite treatment approach, which has sparked buyout speculation and increased bullish sentiment among retail traders. Additionally, Vir is advancing its prostate cancer candidate, VIR-5500, with pivotal trials expected in 2027, adding to its long-term growth prospects.

Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ)

https://seekingalpha.com/news/4668779-vir-biotechnology-reports-positive-hepatitis-results-early-signs-of-possible-cure
Vir Biotechnology announced positive results from its experimental combination treatment for chronic hepatitis delta. A Phase 3 trial met its primary goal, with 44% of patients achieving undetectable virus and normalized liver enzymes. Separately, a Phase 2 study showed sustained viral suppression in patients who stopped treatment, with all 10 patients remaining virus-free at 12 weeks and seven at 24 weeks, hinting at a potential cure.

Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data

https://www.quantisnow.com/insight/vir-biotechnology-announces-expanded-phase-2-solstice-data-for-elebsiran-6779803
Vir Biotechnology reported expanded Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta, showing that all 28 patients completing Week 96 of combination therapy achieved undetectable virus. Exploratory data also suggested potential curative effects after treatment cessation, with 10 out of 10 patients sustaining a response. The company plans a conference call on November 9, 2026, to discuss these results alongside topline Phase 3 ECLIPSE 1 results, which met all endpoints.

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

https://www.quantisnow.com/insight/vir-biotechnology-announces-primary-endpoint-met-in-pivotal-phase-3-6779801
Vir Biotechnology announced that its pivotal Phase 3 ECLIPSE 1 trial for elebsiran and tobevibart in adults with chronic hepatitis delta met its primary endpoint with statistically significant results. The company plans a comprehensive regulatory filing for U.S. FDA submission in mid-2027. The treatment was well-tolerated, with 79% of patients achieving undetectable virus at Week 48.
Advertisement

Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call

https://www.biospace.com/press-releases/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call
Vir Biotechnology (Nasdaq: VIR) announced it will present topline Phase 3 ECLIPSE 1 trial data for its combination therapy of elebsiran and tobevibart for chronic hepatitis delta at The Liver Meeting® 2026. The company will also present expanded Phase 2 SOLSTICE data in two additional oral presentations. An investor conference call is scheduled for November 9, 2026, to discuss these results.

Vir Biotechnology stock hits 52-week high at 12.19 USD By Investing.com

https://ca.investing.com/news/stock-market-news/vir-biotechnology-stock-hits-52week-high-at-1219-usd-93CH-4939992
Vir Biotechnology Inc. (VIR) has achieved a 52-week high of $12.19, reflecting a significant 137.23% appreciation over the past year and an 83% year-to-date return. Despite this surge and a market capitalization of $2.09 billion, InvestingPro analysis suggests the stock is overvalued and the company remains unprofitable over the last twelve months, although it holds more cash than debt. The company recently reported a narrower quarterly loss for Q3 2026, surpassing analyst expectations, driven by advancements in its hepatitis delta and oncology pipelines.

This Insider Has Just Sold Shares In Vir Biotechnology

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/this-insider-has-just-sold-shares-in-vir-biotechnology
Vir Biotechnology's Executive VP, Vanina de Verneuil, recently sold US$42k worth of stock at US$11.18 per share, reducing her holding by 3.3%. This follows a larger sale by Independent Chairman Vicki Sato for US$221k last year, which was slightly below the current share price. While there's been some insider selling, the overall insider ownership of 4.2% (worth US$79m) indicates some alignment between management and shareholders, despite no insider buying in the last year.

Vir Biotechnology EVP Vanina de Verneuil sells $41,938 in company stock

https://www.investing.com/news/insider-trading-news/vir-biotechnology-evp-vanina-de-verneuil-sells-41938-in-company-stock-93CH-5004227
Vanina de Verneuil, EVP at Vir Biotechnology, sold $41,938 worth of company stock in early November 2026. These sales included an automatic transaction to cover tax obligations and another executed under a Rule 10b5-1 trading plan. The transactions occurred while VIR stock was trading near its 52-week high after a significant 118% gain over the past year.

Vir Biotechnology Narrows Third-Quarter Net Loss to $96.3 Million

https://www.tokenpost.com/news/business/49612
Vir Biotechnology reported a narrower third-quarter net loss of $96.3 million, or $0.57 per share, significantly down from $163.1 million or $1.17 per share in the previous year. This improvement was primarily due to a reduction in research and development expenses. The company also announced that its cash, cash equivalents, and investments of $901.3 million are expected to fund operations into the second half of 2028.
Advertisement

Vir Bio (VIR) Q3 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/8678780/vir-bio-vir-q3-2026-earnings-call-transcript/
Vir Biotechnology reported its Q3 2026 financial results, highlighting a cash runway into the second half of 2028 and significant progress in its clinical pipeline, particularly for chronic hepatitis delta and prostate cancer. The company secured a strategic collaboration with Gilead, involving a $90 million upfront payment and potential milestones up to $1.74 billion, validating its PRO-XTEN T-cell engager platform. Upcoming catalysts include top-line data from its Phase III ECLIPSE program in hepatitis delta and plans for multiple Phase III studies for VIR-5500 in prostate cancer.

Form 4 Vir Biotechnology Inc: Vanina de Verneuil (EVP, General Counsel, Corp Sec) For: 2 November

https://ca.investing.com/news/stock-market-news/form-4-vir-biotechnology-inc-vanina-de-verneuil-evp-general-counsel-corp-sec-for-2-november-93CH-4934908
This article reports on a Form 4 filing for Vir Biotechnology Inc, detailing an insider transaction by Vanina de Verneuil, EVP, General Counsel, and Corporate Secretary. The filing pertains to activity on November 2nd. The article provides the title and the name of the executive involved in the transaction.

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

https://www.biospace.com/press-releases/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2026-financial-results
Vir Biotechnology reported its third-quarter 2026 financial results, highlighting key advancements in its pipeline, including anticipated topline data from the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta in Q4 2026. The company also announced that VIR-5500 received Fast Track designation and achieved proof of concept in oncology, with pivotal trials set to begin next year. Vir ended the quarter with approximately $901 million in cash, cash equivalents, and investments, bolstered by a new collaboration and license agreement with Gilead.

With $239M in Astellas revenue, Vir Biotechnology (VIR) narrowed its nine-month loss.

https://www.stocktitan.net/sec-filings/VIR/10-q-vir-biotechnology-inc-quarterly-earnings-report-14d0b2210d62.html
Vir Biotechnology (VIR) reported a significant narrowing of its nine-month net loss to $141.9 million in 2026, down from $395.1 million in 2025, driven by a substantial increase in revenue to $238.7 million, primarily from a collaboration with Astellas. The company's cash and investments total approximately $901.3 million, which is expected to fund operations for at least 12 months. Additionally, Vir announced new collaborations with Gilead Sciences for T-cell engager candidates and provided updates on its chronic hepatitis delta and oncology clinical programs.

Vir Biotechnology Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62897227/vir-biotechnology-q3-2026-earnings-call-transcript
Vir Biotechnology reported substantial advancements in its hepatitis delta and oncology programs, with Phase 3 trials underway for hepatitis delta and key data expected soon. The company announced a strategic collaboration with Gilead, including $90 million upfront and potential milestones up to $1.74 billion, significantly boosting financial flexibility. R&D expenses were reduced, and the company ended the quarter with $901 million in cash, positioning it for future growth and pipeline development.
Advertisement

Vir Biotechnology (NASDAQ:VIR) EVP Sells $26,717.70 in Stock

https://www.marketbeat.com/instant-alerts/insider-vir-biotechnology-nasdaq-vir-evp-sells-2671770-in-stock-2026-11-04/
Vir Biotechnology's EVP, Vanina de Verneuil, sold 2,407 shares of company stock totaling $26,717.70, reducing her stake by 2.14%. This transaction was conducted under a pre-arranged Rule 10b5-1 plan to cover tax obligations from vested equity awards. The company's shares rose 3.3% to $11.59, and it recently exceeded EPS and revenue estimates, holding a consensus "Moderate Buy" rating from analysts with an average price target of $21.86.

VIR general counsel de Verneuil sold $41.9K of shares (Form 4)

https://www.quantisnow.com/insight/evp-general-counsel-corp-sec-de-verneuil-vanina-sold-41939-6772015
Vir Biotechnology's EVP, General Counsel, and Corporate Secretary, Vanina de Verneuil, sold 3,750 shares of VIR stock for $41.9K at an average price of $11.18. This transaction, conducted under a 10b5-1 plan between November 2-3, 2026, was primarily to satisfy tax withholding obligations related to the vesting of restricted stock units. Following the sales, de Verneuil directly holds 110,193 shares of Vir Biotechnology.

Is Vir Biotechnology (VIR) Undervalued On Its Board Appointment And Oncology Focus?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/is-vir-biotechnology-vir-undervalued-on-its-board-appointmen
Vir Biotechnology's stock is gaining renewed investor attention following the appointment of cancer immunotherapy expert Dr. Suzanne Topalian to its Board of Directors, highlighting the company's oncology ambitions. Despite recent share price choppiness, the stock has seen significant gains year-to-date and over the past year. With an upcoming Q3 2026 earnings release and participation in a major healthcare conference, investors are reevaluating the company's infectious disease pipeline and oncology focus, with the market currently valuing it as 47% undervalued.

After selling 1,343 shares, a Vir Biotechnology (VIR) officer proposes a $26.7K sale.

https://www.stocktitan.net/sec-filings/VIR/144-vir-biotechnology-inc-sec-filing-23793ece3441.html
Vir Biotechnology officer Vanina A. Huard de Verneuil has proposed selling 2,407 common shares, valued at approximately $26,717.70, with an anticipated sale date of November 3, 2026. This proposed sale follows a recent transaction on November 2, 2026, where de Verneuil sold 1,343 common shares for $15,221.96. The company's total shares outstanding are reported at 169,215,958.

Form 144 Vir Biotechnology For: 3 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-vir-biotechnology-for-3-november-93CH-4951684
This article from Investing.com announces the filing of Form 144 by Vir Biotechnology for November 3rd. It provides minimal details beyond the announcement, indicating that the form relates to the company's stock activity. The article also mentions that Vir Biotechnology's stock (VIR) is down 2.65% in the context of this announcement.
Advertisement

A London healthcare conference will feature Vir Biotechnology's CEO on Nov. 18.

https://www.stocktitan.net/news/VIR/vir-biotechnology-to-participate-in-the-jefferies-2026-london-sfz209ddvlmg.html
Vir Biotechnology (Nasdaq: VIR) announced that its President and CEO, Marianne De Backer, will present at the Jefferies 2026 London Healthcare Conference on November 18, 2026. The presentation will be a fireside chat held at 10:30 a.m. GMT / 5:30 a.m. ET, with a live webcast available for 30 days. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer.

An officer proposes selling 1,343 shares of Vir Biotechnology (NASDAQ: VIR).

https://www.stocktitan.net/sec-filings/VIR/144-vir-biotechnology-inc-sec-filing-0a6a1ef5e87b.html
Vanina Huard de Verneuil, an officer at Vir Biotechnology, Inc., has proposed selling 1,343 common shares with an aggregate market value of $15,221.96. The proposed sale, scheduled for November 2, 2026, is intended to cover a tax obligation from a vested equity award distribution. Fidelity Brokerage Services LLC is listed as the broker for this transaction.

Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference

https://www.biospace.com/press-releases/vir-biotechnology-to-participate-in-the-jefferies-2026-london-healthcare-conference
Vir Biotechnology, Inc. announced that its President and CEO, Marianne De Backer, will present at the Jefferies 2026 London Healthcare Conference on November 18, 2026. A live webcast of the fireside chat will be available on the company's investor relations website. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases and cancer.

Form 4 Vir Biotechnology Inc: Suzanne Louise Topalian (Director) For: 27 October

https://ng.investing.com/news/stock-market-news/form-4-vir-biotechnology-inc-suzanne-louise-topalian-director-for-27-october-93CH-2764579
This article reports on a Form 4 filing for Vir Biotechnology Inc., indicating an insider transaction by Director Suzanne Louise Topalian on October 27. The Form 4 is a document required by the SEC to disclose changes in beneficial ownership of a company's securities by its directors, officers, and principal shareholders.

Vir Biotechnology stock hits 52-week high at $12.02

https://www.investing.com/news/company-news/vir-biotechnology-stock-hits-52week-high-at-1202-93CH-4984086
Vir Biotechnology Inc. (VIR) stock reached a 52-week high of $12.02, reflecting a 102% increase over the past year. Despite InvestingPro suggesting the shares are slightly overvalued, the company maintains a strong financial position with a $2.01 billion market cap and more cash than debt. Recent positive developments include improved Q2 2026 financials due to an Astellas collaboration, increased price targets from analysts like H.C. Wainwright and Raymond James, and a new board appointment.
Advertisement

Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

https://www.biospace.com/press-releases/vir-biotechnology-announces-appointment-of-suzanne-topalian-to-its-board-of-directors
Vir Biotechnology, Inc. announced the appointment of Dr. Suzanne Topalian to its Board of Directors, effective October 27, 2026. Dr. Topalian is a highly respected leader in cancer immunotherapy, recognized for her foundational research on anti-tumor immunity and PD-1 blockade. Her extensive expertise will be invaluable as Vir Biotechnology continues to develop its oncology portfolio and advance new therapeutic approaches for cancer patients.

Vir Biotechnology Appoints Cancer Immunotherapy Expert Suzanne Topalian to Board

https://www.citybiz.co/article/926030/vir-biotechnology-appoints-cancer-immunotherapy-expert-suzanne-topalian-to-board/
Vir Biotechnology, Inc. (Nasdaq: VIR) has appointed Dr. Suzanne Topalian, an internationally recognized cancer immunotherapy researcher and physician-scientist, to its Board of Directors. Dr. Topalian brings extensive experience in cancer immunology and the development of immunotherapy treatments, which will be valuable as Vir Biotechnology advances its oncology pipeline, including experimental treatments designed to activate the immune system against solid tumors. Her foundational research on PD-1 contributed to immune checkpoint inhibitor therapies, and she will contribute to the company's strategy in developing next-generation cancer immunotherapies using its PRO-XTEN platform.

Form 3 Vir Biotechnology, Inc. For: Oct 27 Filed by: Topalian Suzanne Louise

https://www.streetinsider.com/SEC+Filings/Form+3+Vir+Biotechnology%2C+Inc.+For%3A+Oct+27+Filed+by%3A+Topalian+Suzanne+Louise/27248070.html
Suzanne Louise Topalian, a Director of Vir Biotechnology, Inc. (VIR), filed an Initial Statement of Beneficial Ownership of Securities (Form 3) on October 27, 2026. The filing indicates that Topalian beneficially owns 0 shares of Common Stock directly. This SEC filing serves to report her initial holdings in the company.

Form 4 Vir Biotechnology Inc: Suzanne Louise Topalian (Director) For: 27 October By Investing.com

https://in.investing.com/news/stock-market-news/form-4-vir-biotechnology-inc-suzanne-louise-topalian-director-for-27-october-93CH-5661455
This article reports on a Form 4 filing for Vir Biotechnology Inc, indicating an insider transaction by Director Suzanne Louise Topalian on October 27th. The brief announcement provides no specific details about the nature of the transaction but mentions the company's stock symbol VIR, which showed a 3.11% gain.

Stock options granted by Vir Biotechnology (VIR) carry an $11.57 exercise price.

https://www.stocktitan.net/sec-filings/VIR/form-4-vir-biotechnology-inc-insider-trading-activity-3e0fbaca4fb4.html
Vir Biotechnology's director, Suzanne Louise Topalian, was granted restricted stock units (RSUs) and stock options on October 27, 2026. The awards include 8,000 and 4,731 RSUs, plus options for 16,000 and 9,462 shares, all with an $11.57 exercise price and expiring on October 26, 2036. The vesting schedules vary, with some vesting in installments starting October 27, 2027, and others vesting fully on the earlier of that date or the next annual meeting.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement